S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NASDAQ:ILMN

Illumina - ILMN Stock Forecast, Price & News

$215.74
+7.04 (+3.37%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$206.03
$217.49
50-Day Range
$188.77
$224.94
52-Week Range
$173.45
$371.16
Volume
1.48 million shs
Average Volume
1.30 million shs
Market Capitalization
$33.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$252.32

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
17.0% Upside
$252.32 Price Target
Short Interest
Healthy
2.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.21mentions of Illumina in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$499,481 Sold Last Quarter
Proj. Earnings Growth
-37.05%
From $2.24 to $1.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

338th out of 1,029 stocks

Analytical Instruments Industry

10th out of 28 stocks

ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

Illumina (ILMN) Misses Q4 Earnings Estimates
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
DNA-Reading Giant Illumina Topples On Wide Profit Miss
Illumina (ILMN) to Release Earnings on Tuesday
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Piper Sandler Trims Illumina (NASDAQ:ILMN) Target Price to $290.00
Has Illumina taken the wrong path in its Grail quest?
Analysts Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $253.00
What's in the Cards for Illumina (ILMN) in Q4 Earnings?
Sequencing the Sustainable Secrets of Seaweed
Illumina PT Lowered to $300 at Canaccord Genuity
Should You Hold Illumina (ILMN)?
What’s Happening With Illumina Stock?
Illumina Remains A Sell After 2023 Guidance
Illumina Selected as One of America's Most JUST Companies
5 big earnings reports: Bed Bath & Beyond, Illumina
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,150
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$252.32
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$175.00
Forecasted Upside/Downside
+17.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
15 Analysts

Profitability

Net Income
$762 million
Pretax Margin
-86.87%

Debt

Sales & Book Value

Annual Sales
$4.53 billion
Cash Flow
$7.57 per share
Book Value
$68.71 per share

Miscellaneous

Free Float
157,096,000
Market Cap
$33.94 billion
Optionable
Optionable
Beta
1.13

Social Links


Key Executives

  • Francis A. deSouzaFrancis A. deSouza
    President, Chief Executive Officer & Director
  • Kevin Pegels
    Chief-Global Operations
  • Joydeep Goswami
    Chief Financial & Strategy Officer
  • Phillip G. FebboPhillip G. Febbo
    Chief Medical Officer
  • Alex Aravanis
    CTO, Head-Research & Product Development













ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price forecast for 2023?

15 Wall Street research analysts have issued 12 month price objectives for Illumina's shares. Their ILMN share price forecasts range from $175.00 to $350.00. On average, they anticipate the company's stock price to reach $252.32 in the next year. This suggests a possible upside of 17.0% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2023?

Illumina's stock was trading at $202.20 at the start of the year. Since then, ILMN stock has increased by 6.7% and is now trading at $215.74.
View the best growth stocks for 2023 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its earnings results on Thursday, November, 4th. The life sciences company reported $1.45 earnings per share for the quarter, topping analysts' consensus estimates of $1.24 by $0.21. The life sciences company earned $1.11 billion during the quarter, compared to analysts' expectations of $1.04 billion. Illumina had a positive trailing twelve-month return on equity of 4.36% and a negative net margin of 88.40%. The company's quarterly revenue was up 39.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 earnings per share.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY23 earnings guidance on Tuesday, February, 7th. The company provided earnings per share guidance of $1.25-1.50 for the period, compared to the consensus earnings per share estimate of $1.38. The company issued revenue guidance of +7-10% yr/yr to $4.9-5.04 billion, compared to the consensus revenue estimate of $4.97 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.64%), Veritas Asset Management LLP (0.99%), Ownership Capital B.V. (0.71%), Sarasin & Partners LLP (0.35%), Sumitomo Mitsui Trust Holdings Inc. (0.29%) and Envestnet Asset Management Inc. (0.27%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $215.74.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $33.94 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or ($26.40) on an earnings per share basis.

How many employees does Illumina have?

The company employs 9,150 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 2/8/2023 by MarketBeat.com Staff